References
[1]. J.L. Hinkle & M. Guanci, Acute Ischemic Stroke, Review. J Neurosci Nurs., 39(5), 285-293, 310, 2007.
[2]. P. Liao, C.Y. Yu, G. Ng, Therapeutic antibodies in Stroke, Transl. stroke Res., 4, 477-483, 2013.
[3]. B.W. McColl, S.M. Allan, N.J. Rothwell, Systemic inflammation and stroke: aetiology, pathology and targets for therapy, Biochem Soc Trans., 35(pt 5), 11633-5, 2007.
[4]. H. Offner, A.A. Vandenbark & P.D. Hurn, Effect of experimental stroke on peripheral immunity: CNS ischemia induces profound immunosuppression, Neuroscience, 158(3), 1098-1111, 2009.
[5]. T. Wisniewski, & A. Boutajangout, Vaccination as a therapeutic approach for Alzheimer’s disease, Mt Sinai J Med, 77(1), 17-31, 2012.
[6]. R.L. Sacco, E.J. Benjamin, J.P. Broderick, M. Dyken, J.D. Easton, W.M. Feinberg, et al, Stroke Risk Factors, Stroke, 28, 1507-1517, 1997.
[7]. D.K. Kiely, P.A. Wolf, L.A. Cupples, A.S. Beiser, R.H. Myers, Familial aggregation of stroke: the Framingham Study, Stroke, 24, 1366-1371, 1993.
[8]. A. Kumar, R. Sagar, P. Kumr, J.K. Sahu, A. Grover, A.K. Srivastava, et al, Identification of genetic contribution to ischemic stroke by screening of single nucleotide polymorphisms in stroke patients by using a case control study design, BMC Neurol, 13, 136, 2013.
[9]. K.L. Furie, S.E. Kasner, R.J. Adams, G.W. Albers, R.L. Bush, S.C. Fagan, et al, Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association, Stroke, 42, 227-276, 2011.
[10]. Lobes of the brain, n.d. image from MedlinePlus, viewed 14 April 2014.
[11]. S. Ackerman, Discovering the Brain, Washington (DC): National Academies Press (US), Major Structures and Functions of the Brain, 2, 1992.
[12]. Z. Vrseija, H. Brkic, S. Mrdenovic, R. Radivoje, G. Curic, Function of circle of Willis, J Cereb Blood Flow Metab., 34(4), 578-584, 2014.
[13]. V. Fuster, B. Stein, J.A. Ambrose, L. Badimon, J.J. Badimon, J.H. Chesebro, Atherosclerotic plaque rupture and thrombosis: evolving concepts, Circulation, 82, 47–59, 1990.
[14]. T.M. Dudney, C.G. Elliott, Pulmonary embolism from amniotic fluid, fat, and air, Prog. Cardiovasc. Dis., 36, 447–474, 1994.
[15]. I. Harukuni & A. Bhardwaj, Mechanisms of brain injury after global cerebral ischemia, Neurol Clin, 24, 1-21, 2006.
[16]. K. Hossman, Pathophysiology and therapy of experimental stroke, Cellular and Molecular Neurobiology, 26(7-8), 1057-83, 2006.
[17]. K.J. Zu ̈lch, The Cerebral Infarct. Pathology, Pathogenesis, and Computed Tomography, Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1985.
[18]. U. Dirnagl & W. Pulsinelli, Autoregulation of cerebral blood flow in experimental focal brain ischemia, J. Cereb. Blood Flow Metab., 10, 327–336, 1990.
[19]. K.A. Hossmann, Viability thresholds and the penumbra of focal ischemia, Ann. Neurol. 36, 557– 565, 1994b.
[20]. G. Mies, T. Iijima, and k.A. Hossmann, K, Correlation between periinfarct DC shifts and ischemic neuronal damage in rat, NeuroReport 4, 709–711, 1993.
[21]. R. Gonzalez, Imaging-Guided Acute Ischemic Stroke Therapy: From “Time Is Brain” to “Physiology Is Brain”, Am J Neuroradiol, 27, 728-735, 2006.
[22]. J.N. Kew & J.A. Kemp, Ionotropic and metabotropic receptor structure and pharmacology, Psychopharmacology (Berl), 179(1), 4-29, 2005.
[23]. P.H. Chan, Role of oxidants in ischemic brain damage. Stroke 27, 1124–1129, 1996.
[24]. Y.H. Kim, E.Y. Kim, B.J. Gwag, S. Sohn, and J.Y. Koh, Zinc-induced cortical neuronal death with features of apoptosis and necrosis, mediation by free radicals, Neuroscience 89, 175–182, 1999.
[25]. M. Tomita, Pathophysiology of brain edema. In: Kalimo, H. (Ed.), Cerebrovascular Diseases, ISN Neuropath, Basel, Switzerland, 33–46, 2005.
[26]. G.Y. Yang, G.P. Schielke, C. Gong, Y. Mao, H.L. Ge, C.H. Liu, and A.L. Betz, Expression of tumor necrosis factor-alpha and intercellular adhesion molecule-1 after focal cerebral ischemia in interleukin-1 beta converting enzyme deficient mice, J. Cereb. Blood Flow Metab. 19, 1109–1117, 1999.
[27]. E. Kolackowska & Kubes, Neutrophil recruitment and function in health and inflammation, Nature reviews Immunology, 13, 159-175, 2013.
[28]. E.J. Kunkel & E.C. Butcher, Plasma-cell homing, Nature Reviews Immunology, 3, 822-829, 2003.
[29]. O. Barreiro & F. Sanchez-Madrid, Molecular Basis of Leukocyte-Endothelium Interactions During the Inflammatory Response, Rev Esp Cardiol., 62(5), 552-62, 2009.
[30]. D.G. Woodside & P. Vanderslice, Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive disease, Biodrugs, 22(2), 85-100, 2008.
[31]. A. Stemer, & P. Lyden, Evolution of the thrombolytic treatment window for acute ischemic stroke, Curr. Neurol. Neurosci. Rep., 10, 29–33, 2010.
[32]. W. Hacke, M. Kaste, C. Fieschi, Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke, The European Cooperative Acute Stroke Study (ECASS) JAMA. 274, 1017–1025, 1995.
[33]. D. Collen & H.R. Lijnen, History of Discovery: The Tissue-Type Plasminogen Activator Story, Arteriosclorosis, thrombosis, and Vascular Biology, 29, 1151-1155, 2009.
[34]. K. Benchenane, H. Castel, M. Boulouard, R. Bluthe, M. Fernaandez-Monreal, B.D. Roussel, et al, Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory, J Cell Sci, 120, 578-585, 2007.
[35]. H. Takeda, M. Spatz, C. Ruetzler, R. McCarron, K. Becker, J. Hallenbeck, Induction of mucosal tolerance to E-selectin prevents ischemic and hemorrhagic stroke in spontaneously hypertensive genetically stroke- prone rats, Stroke, 33, 2156–63, 2002.
[36]. A. Vila-Corcoles, O. Ochoa-Gondar, T. Rodriguez-Blanco, A. Giutierrez-Perez, A. Vila-Rovira, F. Gomez, et al, Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up, BMC Public Health, 12, 222, 2012.
[37]. T. GrandPre, F. Nakamura, T. Vartanian, S.M. Strittmatter, Identification of the Nogo inhibitor of axon regeneration as a reticulon protein, Nature, 403, 439–44, 2000.
[38]. S.Y. Tsai, T.M. Markus, E.M. Andrews, L. Cheatwood, A.J. Emerick, A.K. Mir, et al, Intrathecal treatment with anti-Nogo-A antibody improves functional recovery in adult rats after stroke, Exp Brain Res., 182, 261–6, 2007.
[39]. Ma, J., Tian, W., M., Hou, S., P., Xu, Q., Y., Spector, M., Cui, F., Z. 2007. An experi- mental test of stroke recovery by implanting a hyaluronic acid hy- drogel carrying a Nogo receptor antibody in a rat model. Biomed Mater., 2, 233–40.
[40]. J. Zhang & J.S. Diamond, Distinct perisynaptic and synaptic localisation of NMDA and AMPA receptors on ganglion cells in rat retina, J Comp Neurol., 498(6), 810-820, 2006.
[41]. W. Paschen, Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic- cell damage, Med. Hypotheses, 47, 283–288, 1996.
[42]. M.J. During, C.W. Symes, P.A. Lawlor, J. Lin, J. Dunning, H.L. Fitzsimons, et al, An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy, Science, 287, 1453–60, 2000.
[43]. R. Macrez, P. Obiang, M. Gauberti, B. Roussel, A. Baron, J. Parcq, et al, Antibodies preventing the interaction of tissue-type plasminogen activator with N -methyl-D -aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis, Stroke, 42, 2315–22, 2011.
[44]. Y. Matsuo, T. Kihara, M. Ikeda, M. Ninomiya, H. Onodera, K. Kogure, Role of neutrophils in radical production during ischemia and reper- fusion of the rat brain: effect of neutrophil depletion on extracellular ascorbyl radical formation, J Cereb Blood Flow Metab., 15, 941–7, 1995.
[45]. Y. Matsuo, H. Onodera, Y. Shiga, M. Nakamura, M. Ninomiya, T. Kihara, et al, Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion, Stroke, 25, 1469–75, 1994.
[46]. H. Suzuki, K. Abe, S.J. Tojo, H. Kitagawa, K. Kimura, M. Mizugaki, et al, Reduction of ischemic brain injury by anti-P-selectin monoclo- nal antibody after permanent middle cerebral artery occlusion in rat, Neurol Res., 21, 269–76, 1999.
[47]. J. Huang, T.F. Choudhri, C.J. Winfree, R.A. McTaggart, S. Kiss, J. Mocco, et al, Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke, Stroke, 31, 3047–53, 2000.
[48]. Bednar, M., M., Gross, C., E., Russell, S., R., Fuller, S., P., Ellenberger, C., L., Schindler, E., et al. 1998. Humanized anti-L-selectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke. Neurol Res., 20, 403–8, 1998.
[49]. R.L. Zhang, M. Chopp, N. Jiang, W.X. Tang, J. Prostak, A.M. Manning, et al, Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not perma- nent middle cerebral artery occlusion in the Wistar rat, Stroke, 26, 1438–42, 1995.
[50]. M. Chopp, Y. Li, N. Jiang, R.L. Zhang, J. Prostak, Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain, J Cereb Blood Flow Metab, 16, 578–84, 1996.
[51]. M.K.T. Squier, A.J. Sehnert, J.J. Cohen, Apoptosis in leukocytes, J Leuk Biol, 57, 2–10, 1995.
[52]. H.H. Birdsall, Induction of ICAM-1 on human neural cells and mechanisms of neutrophil-mediated injury, Am J Pathol, 139, 1341–1350, 1991.
[53]. M.P. Bowes, R. Rothlein, S.C. Fagan, J.A. Zivin, Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic in- jury and enhance efficacy of thrombolytic therapy, Neurology, 45, 815–9, 1995.
[54]. M. Chopp, R.L. Zhang, H. Chen, Y. Li, N. Jiang, J.R. Rusche, Postischemic administration of an anti-Mac-1 antibody reduces is- chemic cell damage after transient middle cerebral artery occlusion in rats, Stroke, 25, 869–75, 1994.
[55]. J. Hill, T. Lindsay, J. Rusche, C.R. Valeri, D. Shepro, H.B. Hechtman, A mac-1 antibody reduces liver and lung injury but not neutrophil sequestration after intestinal ischemia-reperfusion, Surgery, 112, 166-172, 1992.
[56]. Y. Yamasaki, Y. Matsuo, J. Zagorski, N. Matsuura, H. Onodera, Y. Itoyama, et al, New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats, Brain Res., 759, 103–11, 1997.
[57]. A.J. Bruce, W. Boling, M.S. Kindy, M, J. Peschon, P.J. Kraemer, M.K. Carpenter, F.W. Holtsberg & M.P. Mattson, Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors, Nat Med, 2, 788−794, 1996.
[58]. S.D. Lavine, F.M. Hofman, B.V. Zlokovic, Circulating antibody against tumor necrosis factor-alpha protects rat brain from reperfusion injury, J Cereb Blood Flow Metab, 18, 52–8, 1998.
[59]. T. Iizuka, F. Sakai, T. Ide, T. Monzen, S. Yoshii, M. Iigaya et al, Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal, Neurology, 70, 4–11, 2008.
[60]. L.H. Sansing, E. Tüzün, M.W. Ko, J. Baccon, D.R. Lynch, J. Dalmau, A patient with encephalitis associated with NMDA receptor antibodies, Nat Clin Pract Neurol., 3, 291–96, 2007.
[61]. E.G. Hughes, X. Peng, A.J. Gleichman, M. Lai, L. Zhou, R. Tsou, et al, Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis, J Neurosci. 30, 5866–75, 2010.
[62]. Enlimomab Acute Stroke Trial Investigators, Use of anti-ICAM-1 therapy in ischemic stroke, Neurology, 23, 57(8), 1428-34, 2001.
[63]. B. Fellerhoff, B. Laumbacher & R. Wank, Responsiveness of a patient in a persistent vegetative state after a coma to weekly injections of autologous activated immune cells: a case report, Journal of Medical Case Reports, 6, 6, 2012.
[64]. Y.Y. Chye, G. Ng, P. Liao, Therapeutic antibodies in stroke, Transl, Stroke Res., 4, 477-483, 2013.